12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$18M | 6.0% | -896.6% | -54.3% | -44.2% | -$9M | — | $4M |
| 2024 | $3M | -$4M | 59.0% | -140.0% | -590.9% | -102.1% | -$3M | — | $752000 |
| 2023 | $2M | -$4M | 67.3% | -150.5% | -93.0% | -55.6% | -$4M | — | — |
| 2022 | $752000 | -$5M | 22.2% | -666.5% | -168.5% | -92.7% | -$7M | — | — |
| 2021 | $2M | -$14M | 45.4% | -335.3% | -226.2% | -165.6% | -$4M | — | $8M |
| 2020 | $623000 | -$4M | 34.3% | -757.5% | -180.7% | -52.6% | -$3M | — | $7M |
| 2019 | $530000 | -$6M | 53.0% | -971.9% | -430.1% | -284.6% | — | — | $1M |
| 2018 | $318000 | -$4M | 50.3% | -1353.1% | -897.2% | -262.9% | -$4M | — | $896000 |
| 2017 | — | -$5M | — | — | -136.6% | -102.1% | — | — | $4M |
| 2016 | — | -$3M | — | — | 113.3% | -573.1% | -$2M | — | $106000 |
| 2015 | — | -$3M | — | — | 1379.9% | -145.4% | — | — | $2M |
| 2014 | — | -$3M | — | — | 47.1% | -366.1% | — | — | $90000 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $239000 | -$5M | -111.3% | -2290.4% | -15.9% | -12.8% | -$3M | — | $1M |
| Mar '26 | $653000 | -$4M | -8.4% | -568.3% | -11.9% | -9.6% | -$4M | — | $2M |
| Dec '25 | $312000 | -$13M | -118.6% | -4748.1% | -38.4% | -31.3% | -$3M | — | $4M |
| Sep '25 | $722000 | $510000 | 26.2% | -311.2% | 1.2% | 0.9% | -$2M | — | $7M |
| Jun '25 | $494000 | -$4M | -7.1% | -804.9% | -9.8% | -7.7% | -$3M | — | $4M |
| Mar '25 | $1M | -$2M | 36.0% | -180.7% | -5.2% | -4.2% | -$1M | $1M | $571000 |
| Dec '24 | $444000 | -$1M | 63.7% | -308.6% | -228.2% | -39.4% | -$548000 | — | $752000 |
| Sep '24 | $376000 | -$998000 | 35.4% | -258.0% | -53.3% | -21.3% | -$836000 | — | $1M |
| Jun '24 | $817000 | -$688000 | 52.4% | -82.5% | -24.2% | -12.1% | -$555000 | — | — |
| Mar '24 | $921000 | -$588000 | 72.1% | -61.7% | -16.8% | -9.4% | -$580000 | — | — |
| Dec '23 | $1M | -$813000 | 62.6% | -59.6% | -20.4% | -12.2% | -$491000 | — | — |
| Sep '23 | $458000 | -$727000 | 76.2% | -146.3% | -15.5% | -9.9% | -$682000 | — | — |
| Jun '23 | $294000 | -$1M | 73.5% | -343.2% | -92.2% | -28.0% | -$1M | — | — |
| Mar '23 | $354000 | -$1M | 66.4% | -298.0% | -49.8% | -22.8% | -$1M | — | — |
| Dec '22 | -$102000 | -$2M | 294.1% | 1674.5% | -63.7% | -35.0% | -$1M | — | — |
| Sep '22 | $97000 | -$955000 | 82.5% | -952.6% | -30.3% | -18.3% | -$2M | — | $2M |
| Jun '22 | $485000 | -$1M | 57.9% | -261.4% | -31.5% | -19.9% | — | — | $4M |
| Mar '22 | $272000 | -$1M | 39.0% | -408.8% | -21.5% | -14.8% | — | — | $6M |
| Dec '21 | $775000 | -$2M | 33.2% | -323.9% | -39.2% | -28.7% | -$863000 | — | $8M |
| Sep '21 | $499000 | -$7M | 45.7% | -173.9% | -76.6% | -69.1% | -$635000 | — | $9M |
How the market has priced FEED against its own fundamentals since 2025-12 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, ENvue Medical, Inc.'s revenue has grown 32.6% per year. These are computed facts, not advice.
As of FY2025, ENvue Medical, Inc. reported — of total debt against $4M of cash.
In FY2025, gross margin was 6.0%, operating margin -896.6%, and net margin -712.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.